Reminder: Do not include any PHI or PII in Confluence. If you require 508 accessibility assistance or any other support for this system, then please send an email to onc-jira-questions@healthit.gov
...
- Given that the data in the registry is obtained under a mixture of informed consent, waivers, and business associate agreements, how should these conditions be tracked?
- Given that the registry contains PRO data, which in some cases patients have consented for research use (and in other cases not), what, if any, are the researcher’s obligations for the use of data without explicit patient consent? How should the entity managing the registry deal with consent and data use?
- Does the fee affect real or perceived ethical concerns?
- Would concerns be different if the research obtained IRB approval for use of deidentified data, with some concerns for re-identification?
- Do concerns differ if the PROs include instruments intended to measure post-surgical depression?
- What additional protections must be in place given the availability of the limited data set?
Title | Response |
Description | A registry contains health data and PROs approved for research purposes, and each record has been approved under different conditions. |
Primary actor/participant | Researcher (end-user) using registry |
Support actor/participant | Registry-affiliated entities who submit clinical data, patients who submit PRO data |
Preconditions |
|
Post conditions |
|
Alternatives |
|
Considerations |
|
Data Elements Considered | Electronic data from multiple sites and patient reported outcomes, |
Purpose of the Data Collection | Improved clinical care and patient outcomes
|
Purpose of Data Use | Analysis under a specific research protocol |
Terms of Transfer to the Data Holders | DUA between organizations, informed consent |
Terms of Transfer to Researchers | IRB approval and terms of consent or other agreements |
...